Teva Pharmaceutical Industries Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Richard Francis

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	3.2yrs
Promedio de permanencia en la Junta Directiva	6.4yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Richard Francis (55 yo)

less than a year

Permanencia

Mr. Richard D. Francis serves as President and Chief Executive Officer at Teva Pharmaceutical Industries Limited since January 01, 2022 and serves as its Director. He was Chief Executive Officer of Sandoz...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Eliyahu Kalif	Executive VP & CFO	4yrs	US$4.01m	0.0089% $ 905.0k
Eric Drape	Executive Vice President of Global Operations	4.2yrs	US$3.91m	0.015% $ 1.6m
Mark Sabag	Executive Vice President of International Markets Commercial	2.3yrs	US$3.92m	0.029% $ 2.9m
Richard Francis	President	less than a year	sin datos	sin datos
Amir Weiss	Senior VP & Chief Accounting Officer	2.1yrs	sin datos	0.0038% $ 387.6k
Ran Meir	Head of Investor Relations	no data	sin datos	sin datos
David Stark	Executive VP & Chief Legal Officer	7.1yrs	sin datos	0.00027% $ 27.6k
Kathleen Veit	Senior Vice President	1.4yrs	sin datos	sin datos
Vikki Conway	Acting Head of Global Human Resources	less than a year	sin datos	sin datos
Kevin Mannix	Senior Vice President of Investor Relations	no data	sin datos	sin datos
Nir Baron	Senior VP & Chief Internal Auditor	9.6yrs	sin datos	sin datos
Richard Daniell	Executive Vice President of European Commercial	6.1yrs	sin datos	0.0062% $ 636.1k

3.2yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de TEV se considera experimentado (3.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Richard Francis	President	no data	sin datos	sin datos
Sol Barer	Independent Chairman of the Board	8.9yrs	US$540.00k	0.033% $ 3.4m
Amir Elstein	Independent Director	14.9yrs	US$360.00k	0.18% $ 18.9m
Gerald Lieberman	Independent Director	8.3yrs	US$355.00k	0.0076% $ 775.2k
Roberto Mignone	Independent Director	6.4yrs	US$340.00k	0.0066% $ 680.1k
Rosemary Crane	Independent Director	8.3yrs	US$350.00k	0.0074% $ 752.7k
Janet Vergis	Independent Director	3.5yrs	US$315.00k	0.0038% $ 391.7k
Tal Zaks	Independent Director	2.2yrs	US$330.00k	0.0025% $ 255.7k
Perry Nisen	Independent Director	6.4yrs	US$320.00k	0.0066% $ 680.1k
Ronit Satchi-Fainaro	Independent Director	5.5yrs	US$310.00k	0.0060% $ 612.6k
Varda Shalev	Independent Director	less than a year	sin datos	sin datos

6.4yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de TEV se considera experimentada (6.4 años de antigüedad promedio).

Teva Pharmaceutical Industries Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Teva Pharmaceutical Industries Limited, Annual General Meeting, Jun 06, 2024

Teva Pharmaceutical Industries Ltd. Appoints R. Ananthanarayanan (Ananth) as CEO of Its Teva Active Pharmaceutical Ingredients Business

Teva Announces Changes to Executive Management Team

Teva Pharmaceutical Industries Limited Appoints Varda Shalev as Member of the Board, Effective September 1, 2023

Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development, Effective August 1, 2023

Teva Pharmaceutical Industries Limited Appoints Richard Francis as President, Effective January 1, 2023

Recent updates

Teva Pharmaceutical Industries Limited, Annual General Meeting, Jun 06, 2024

Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China

Teva Pharmaceutical Industries Limited to Report Q1, 2024 Results on May 08, 2024

Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

Teva Pharmaceutical Industries Limited Announces Earnings Guidance for Full Year 2024

Court for the District of New Jersey Issues A Decision That Teva Pharmaceuticals Does Not Infringe Any Asserted Claims of Corcept Therapeutics Incorporated’s U.S. Patents

Teva Pharmaceutical Industries Limited Announces Post Hoc Phase 3 Data Analysis Shows AJOVY (Fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-Morbid Obesity

Teva Pharmaceutical Industries Ltd. Appoints R. Ananthanarayanan (Ananth) as CEO of Its Teva Active Pharmaceutical Ingredients Business

Teva Pharmaceutical Industries Limited Announces Phase IV Unite Study Shows Ajovy® (Fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder

Teva Pharmaceutical Industries Limited to Report Q3, 2023 Results on Nov 08, 2023

Teva Announces Changes to Executive Management Team

Teva Pharmaceutical Industries Limited Appoints Varda Shalev as Member of the Board, Effective September 1, 2023

Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Second Quarter Ended June 30, 2023

Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development, Effective August 1, 2023

Teva Pharmaceutical Industries Limited to Report Q2, 2023 Results on Aug 02, 2023

Teva Pharmaceutical Industries Ltd. Announces Further Positive Data from the Pan-European Research Study

Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY

Teva Pharmaceuticals Presents Real-World Data for Austedo (Deutetrabenazine) Tablets with 4-Week Patient Titration Kit At Psych Congress Elevate 2023

Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting

Teva Pharmaceutical Industries Limited Announces That Once-Daily Austedoxr (Deutetrabenazine) Extended-Release Tablets Are Now Available for Adults in the United States

Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2023

Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2023

Teva Pharmaceutical Industries Limited to Report Q4, 2022 Results on Feb 08, 2023

Karo Pharma AB (publ) agreed to acquire of Six brands of Teva for DKK 84 million.

Teva Pharmaceutical Industries Limited Appoints Richard Francis as President, Effective January 1, 2023

Teva Pharmaceutical Industries Limited Revises Earnings Guidance for the Year 2022

Teva Pharmaceutical Industries Limited Reaches Agreement with Arkansas to Settle the State’s Price Fixing Claims

Teva Pharmaceutical Industries Limited to Report Q3, 2022 Results on Nov 03, 2022

Teva Pharmaceutical Industries Limited Presents Studies of Effectiveness of AJOVY for Treatment of Migraine in Patients with Co-morbid Depression

Exelixis, Inc. Files Complaint in the United States District Court for the District of Delaware for Patent Infringement against Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc

Teva Pharmaceutical Industries Limited Announces European Commission Grants Marketing Authorization for Ranivisio (Ranibizumab), for Age-Related Macular Degeneration (AMD) the Most Common Cause of Blindness in Developed Countries

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.19 profit in 2Q 2021)

Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2022

Teva Pharmaceutical Industries Limited Announces Impairment Charges for the Second Quarter Ended June 30, 2022

Teva Pharmaceutical Industries Limited Appoints Eric A. Hughes as Executive Vice President, Global R&D and Chief Medical Officer

Teva Pharmaceutical Industries Limited to Report Q2, 2022 Results on Jul 27, 2022

Teva Pharmaceutical Industries Limited Welcomes the UK Medicines & Healthcare Regulatory Agency Decision to Grant A Licence for Ongavia

Teva Pharmaceutical Industries Limited Revises Earnings Guidance for the Full Year 2022

Teva Pharmaceutical Industries Limited to Report Q1, 2022 Results on May 03, 2022

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2022

Teva Announces Launch of First-To-Market Generic Version of Narcan (Naloxone Hydrochloride Nasal Spray), in the U.S

Teva Pharmaceutical Industries Limited Reaches Agreement with Louisiana to Settle the State’s Opioid-Related Claims

Forecast to breakeven in 2021

Insufficient new directors

Insufficient new directors

Second quarter 2021 earnings released: EPS US$0.19 (vs US$0.13 in 2Q 2020)

Insufficient new directors

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad